Drug intelligence / Profile preview

STK-01

Development stage: Unknown
Lead developer: Sitka Biopharma
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravesical

Overview

STK-01 is a nanoparticle formulation of docetaxel, developed by Sitka Biopharma. It is designed as a lead product for the treatment of bladder cancer, specifically to overcome the poor absorption of existing intravesical chemotherapies. The drug is an HPG-docetaxel nanoparticle formulation, intended to improve the delivery and efficacy of docetaxel in difficult-to-penetrate tissues. Sitka Biopharma, a spin-out from the Centre for Drug Research and Development (CDRD) and the University of British Columbia, is advancing STK-01 into Phase 1 clinical trials with partners like Cancer Research UK (CRUK).

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on STK-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STK-01.

Explore the full profile